ArticleFrontiers in oncology2025
Trends and prediction of incidence and mortality burden of larynx cancer in China and the US: a systematic analysis of the Global Burden of Disease Study 2021.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Epidemiology of ischemic stroke in China and the United States: Global burden, temporal trends, and future projections.Medicine · 2026Article
- Global, regional, and national burden and quality of care index of five head and neck cancers: a 32-year longitudinal analysis.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2026Article
- Integrative analysis identifiedTranslational cancer research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This study aimed to compare and predict the disease burden of larynx cancer in China and the United States (US) using data from the Global Burden of Disease Study 2021 (GBD2021). Methods: We used the data from GBD2021 to systematically analyze and compare the incidence and mortality of laryngeal cancer in China and the United States, and used the Autoregressive Integrated Moving Average (ARIMA) model to predict the trends in the next 10 years. Results: In 2021, China had 38,904.86 (95% UI: 30,369.67-49,486.18) larynx cancer cases and 19,799.45 (95% UI: 15,579.57-25,023.24) deaths, reflecting a 2.52-fold and 53.8% increase from 1990. In the US, there were 16,371.45 (95% UI: 15,509.40-17,060.58) cases and 4,620.32 (95% UI: 4,339.97-4,835.98) deaths, showing a 33.3% and 10.04% increase from 1990. Projections indicate a decline in age-standardized incidence and mortality rates in China, while the US is expected to see a slight decline in incidence but continued significant reductions in mortality. Conclusions: China has a significantly higher number of larynx cancer cases compared to the US, with a higher incidence rate. However, mortality rates are relatively similar. Larynx cancer will remain a notable disease burden in both countries over the next decade.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.